NASDAQ:PLUR Pluri 11/12/2024 Earnings Report $4.95 -0.46 (-8.50%) Closing price 07/18/2025 03:34 PM EasternExtended Trading$4.66 -0.29 (-5.86%) As of 07/18/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Pluri EPS ResultsActual EPS-$1.08Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APluri Revenue ResultsActual Revenue$0.33 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APluri Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsPluri's next earnings date is estimated for Tuesday, September 16, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pluri Earnings HeadlinesPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.July 20 at 2:00 AM | Porter & Company (Ad)Pluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comSee More Pluri Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email. Email Address About PluriPluri (NASDAQ:PLUR) is a clinical-stage biotechnology company dedicated to the development, manufacturing and commercialization of off-the-shelf cell therapy products based on proprietary placental-expanded (PLX) cell lines. Leveraging a three-dimensional cell expansion platform, the company generates PLX cells—mesenchymal-like cells derived from full-term placenta—which exhibit immunomodulatory, pro-angiogenic and anti-inflammatory properties. Pluri’s pipeline includes PLX-PAD for the treatment of critical limb ischemia, muscle regeneration and orthopedic conditions; PLX-R18 targeting hematopoietic recovery following radiation exposure; and PLX-COVID-19 for acute respiratory distress syndrome associated with viral infections. Headquartered in Haifa, Israel, with additional operations in the United States, Pluri operates a fully integrated, cGMP-compliant manufacturing facility capable of producing large-scale cell therapy batches in bioreactors of up to 60,000 liters. This scalable infrastructure underpins the company’s strategy to advance multiple clinical programs in parallel, including ongoing Phase II and Phase III studies across North America and Europe. Pluri has established strategic collaborations with governmental agencies, research institutions and industry partners to support accelerated development through regulatory pathways such as the U.S. FDA’s regenerative medicine advanced therapy (RMAT) designation. Founded in 2001, the company completed its initial public offering on the Nasdaq under the ticker PLUR in early 2024 following the merger of Pluristem Therapeutics and Pluri Biotechnology. Under the leadership of Chief Executive Officer Tal Vaks, Pluri is focused on translating its platform technology into safe, scalable therapies addressing unmet medical needs in cardiovascular, hematological and respiratory indications. With a multicultural team of scientists and industry veterans, Pluri aims to deliver affordable, off-the-shelf cell therapies that can be shipped directly to treatment centers worldwide.Written by Jeffrey Neal JohnsonView Pluri ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.